QPPV.COM KNOWLEDGE ASSESSMENT

Cetuximab: Classification, History, Mechanism, Safety and Pharmacovigilance Knowledge Assessment

Test your understanding of the concepts covered by Cetuximab: Classification, History, Mechanism of Action, Safety and Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 A patient receiving cetuximab and chemotherapy develops a pulmonary event. Which assessment approach is most appropriate?

Attribute the event to cetuximab because pulmonary risk is described in product information Exclude cetuximab because chemotherapy is also known to cause pulmonary toxicity Evaluate cetuximab, co-treatment, pre-existing pulmonary disease, infection and disease-related explanations using chronology and investigations Classify the event as unrelated unless a positive rechallenge occurs

Question 2 of 10 Which action best addresses the failure mode in which a treatment interruption is incorrectly considered complete dechallenge?

Document the interruption, the expected duration of biological effect, rescue measures, co-medication changes and the subsequent clinical course Record only that cetuximab was stopped Assume that persistence of symptoms proves a non-cetuximab cause Exclude dechallenge from the case narrative because it is inherently subjective

Question 3 of 10 Which description best captures the pharmacological identity of cetuximab?

A chimeric IgG1 monoclonal antibody directed against EGFR A fully human small-molecule inhibitor of intracellular EGFR kinase activity A recombinant cytokine that stimulates immune-cell proliferation A radiolabelled antibody that delivers ionising radiation to tumour cells

Question 4 of 10 What is the most defensible conclusion when a cetuximab case has plausible timing but limited objective confirmation and a strong competing explanation?

Record mechanistic plausibility as a hypothesis and express the remaining uncertainty in the medical conclusion Assign definite causality because the event followed exposure Reject any possible contribution because a competing explanation exists Classify the event solely according to whether it appears in product information

Question 5 of 10 Why can tumour biomarker context and treatment line materially affect cetuximab pharmacovigilance interpretation?

They identify the population and treatment setting in which exposure, benefit and competing risks arose They determine whether an adverse event must be considered serious They eliminate the need to record the full combination regimen They are relevant only to clinical development and not post-authorisation surveillance

Question 6 of 10 A case-processing team sends a targeted questionnaire but does not incorporate the returned information into the medical narrative. Why is this a material weakness?

The value of follow-up depends on medically reviewing and integrating information that can change the assessment Questionnaires are valid only when no information is returned Returned information should be stored separately to avoid influencing causality assessment Medical narratives should contain only the initial reporter's wording

Question 7 of 10 A reporting increase is observed for a cetuximab-associated event, but exposure denominators are uncertain and clinical practice recently changed. What is the most appropriate interpretation?

Treat the increase as a hypothesis requiring evaluation, state denominator limitations and examine reporting, practice and population changes Conclude that the incidence has increased because the report count increased Dismiss the increase because spontaneous reports cannot support any signal Convert the report count into a precise rate using the number of treated patients from an unrelated setting

Question 8 of 10 Which set of exposure information most directly supports reconstruction of a potentially product-specific or administration-related event?

Patient initials, tumour type and broad treatment duration Exact product and presentation, batch where available, dose, route, administration date and treatment phase Only the suspected adverse-reaction term and seriousness criterion Only the date on which the case was entered into the safety database

Question 9 of 10 How should rechallenge generally be handled in pharmacovigilance assessment?

Use evidence from routine clinical rechallenge when it occurs, but do not create a rechallenge solely as a pharmacovigilance experiment when clinically inappropriate Always require rechallenge before assigning any causal consideration Treat every retreatment as a controlled rechallenge with definitive evidentiary value Exclude rechallenge information because it cannot contribute to causality

Question 10 of 10 A patient develops an electrolyte abnormality after several cycles of cetuximab while also experiencing diarrhoea. Which reasoning is most appropriate?

The abnormality is necessarily cetuximab-induced because electrolyte disturbance is a recognised risk Diarrhoea automatically excludes any contribution from cetuximab Cetuximab-related effects and gastrointestinal fluid loss should both be assessed using serial results, timing and clinical context The abnormality should be ignored unless it meets a laboratory threshold specified in the article

QPPV.com

Cetuximab: Classification, History, Mechanism, Safety and Pharmacovigilance Knowledge Assessment

Cookie Settings